David Sachs serves as the Chief Financial Officer at IMMUNITYBIO INC, a clinical-stage biotechnology company focused on developing next-generation therapies and vaccines to combat cancer and infectious diseases. With a robust background in finance and biotechnology, Sachs brings a wealth of experience to his role. He has been instrumental in steering the company's financial strategies, ensuring sustainable growth and effective resource allocation to support IMMUNITYBIO's innovative research and development initiatives. Prior to joining IMMUNITYBIO INC, Sachs held several high-profile positions in the finance sector, where he honed his skills in corporate finance, strategic planning, and investor relations. His career includes stints at major financial institutions and biotech firms, where he successfully managed complex financial operations and led teams to achieve corporate objectives. Sachs's ability to navigate the intricate financial landscapes of the biotech industry has been pivotal in his role at IMMUNITYBIO, where he oversees the company's financial health and drives its mission to bring groundbreaking therapies to market. At IMMUNITYBIO INC, Sachs's achievements include spearheading fundraising efforts that have secured significant investments, enabling the company to advance its clinical trials and expand its research capabilities. His strategic foresight and financial acumen have positioned IMMUNITYBIO as a leader in the biotech sector, poised to make significant strides in immunotherapy. Sachs's dedication to the company's vision and his leadership in financial management continue to be vital assets as IMMUNITYBIO works towards transforming patient care and outcomes in oncology and infectious diseases.